Background
==========

Hypertension is the most common risk factor for cardiovascular and cerebrovascular diseases and affected over 1 billion individuals worldwide\[[@B1],[@B2]\]. Although some risk factors of hypertension such as high sodium intake, inactivity, obesity, familial history, etc. have been identified, genetic factors of hypertension at gene level remain unclear. This is possibly partly due to so called \"minor effect\" of the genes\[[@B3]\]. Also, it is possibly due to dilution effect from environment factors because of using a lower cut off of blood pressure to define hypertension cases. However, few studies have examined this hypothesis.

Peroxisome proliferator-activated receptors gamma coactivator 1 alpha (PGC-1*α*, Gene ID, No. 10891) is a coactivator of several nuclear receptors including peroxisome proliferator-activated receptors *α*and *γ*, thyroid hormone receptor, mineral corticoid receptor and estrogen receptors, and was considered involving in blood pressure regulation \[[@B4],[@B5]\]. Recently, several western population studies have studied the associations of Gly482Ser (G482S) and +2962A/G single nucleotide polymorphisms (SNP) of PGC-1*α*gene with blood pressure \[[@B6]-[@B10]\]. However, the associations were inconsistent in different studies, even in the same ethnic populations. Moreover, the association has not been studied in Asian populations.

The aim of this study was to investigate whether the G482S and +2962A/G polymorphisms in the PGC-1*α*gene were associated with blood pressure and the impact of severity of hypertension on the association of PGC-1*α*Gene with blood pressure and risk of hypertension in a middle-aged and elderly population in China.

Methods
=======

Study population
----------------

We drew our study participants from 10 villages in a northern Chinese population in 2004. To be recruited in the study, the participant must be a registered resident and living in the village in the year of survey. Among 8217 registered residents, 2835 met the inclusion criteria of ≥35 years of age, and out of them 2409 were living in the village at the year of survey and thus invited. Among the invited, 1998 accepted to participate and gave their informed consent; and 1701 had their genotypic information. We excluded 59 patients with myocardial infarction and stroke from analyzed population. We also excluded 5 participants with missing data of blood pressure. Finally 1642 participants were included in our analyses. The study was approved by the Ethical Committee of Fuwai Hospital according to the Declaration of Helsinki. The written informed consent was obtained from all participants.

Blood Pressure Measurement
--------------------------

Three BP measurements were obtained from each participant using a standard mercury sphygmomanometer by trained and certified observers, according to a standard protocol described in detail elsewhere\[[@B11],[@B12]\]. The average of the 3 blood pressure readings were used to define hypertension and for analysis in the present paper. Current use of antihypertensive medication was determined by a \"yes\" or \"no\" answer to the Chinese equivalent of the question, \"Have you taken antihypertensive drugs in the past 2 weeks?\"

To explore the impact of severity of hypertension on the association between the gene and hypertension (or blood pressure), we used different cut offs to define hypertension. First, we defined hypertension using the current widely accepted criteria \[[@B2]\] as SBP ≥ 140mmHg or DBP ≥ 90 mmHg or current use of antihypertensive medications. We referred it as \"regular hypertension\" in this paper. Then, we also defined hypertension as SBP ≥ 160mmHg or DBP ≥ 100mmHg regardless of using antihypertensive medication. We referred it as \"severe hypertension\" in this paper.

Body Mass Index (BMI)
---------------------

Body height was measured to the nearest centimeter (cm) using a standard right-angle device. Body weight was measured to the nearest kilogram by using a spring balance. Each participant was measured in typical indoor clothing, without shoes, and in a standing position. BMI was defined as weight/height^2^(kg/m^2^).

Genotyping
----------

We genotyped the G482S (refSNP ID: rs8192678) and +2962A/G (refSNP ID: rs6821591) polymorphisms in the PGC-1*α*gene using DNA MassARRAY Technology\[[@B13],[@B14]\]. Briefly, a fragment (approximately 100bp) containing the SNP site was amplified by PCR first. All PCR reactions were performed on an ABgene (\#TF-0384), 384 well PCR plate. The sample plate and a 384 SpectroCHIP were placed on the deck of the SpectroPOINT robot. The robot transferred a few nanolitres of solution from the sample plate onto the chip and calibrant was transferred from reservoir onto calibrant patches of 384 SpectroCHIP. The chip was read in the Bruker Autoflex Mass Spectrometer system.

Statistical Analysis
--------------------

SHEsis software\[[@B15]\] was used for Hardy-Weinberg equilibrium test, haplotype construction, and linkage analyses. Chi-square test (*χ*^2^) and odds ratio (OR) test were used for dichotomous variables. Logistic regression and ANOVA were used for adjustment for multiple covariates including sex, age, body mass index (BMI), and antihypertensive treatment, using Version 9.0 of SAS system for Windows. A p-value less than 0.05 was considered statistically significant. Statistical power was calculated according to the following formula.

$$\text{Z}_{\text{1} - \beta} = \frac{\sqrt{\text{n}}(\text{p}_{\text{1}} - \text{p}_{\text{2}}) - \text{Z}_{\text{1} - \frac{\alpha}{\text{2}}}\sqrt{\text{2p}(\text{1} - \text{p})}}{\sqrt{\text{p}_{\text{1}}(\text{1} - \text{p}_{\text{1}}) + \text{p}_{\text{2}}(\text{1} - \text{p}_{\text{2}})}}$$

In this formula, n is the total number of participants, p is total prevalence of hypertension, p~1~and p~2~are prevalence of hypertension in two compared genotypes groups, *α*= 0.05 was permitted as possibility of type I errors (Z~1-*α*/2~= 1.96). Then Z~1-*β*~is calculated and statistical power is estimated.

The difference of ORs was tested using Z-test according to the following formula.

$$Z = \frac{\ln OR_{1} - \ln OR_{2}}{\sqrt{\sigma_{\ln OR1}^{2} + \sigma_{\ln OR2}^{2}}}$$

Results
=======

General characteristics of participants
---------------------------------------

Table [1](#T1){ref-type="table"} showed general characteristics of the participants. Briefly, 648 men and 994 women participated in the study. The age varied from 35 to 91 years and was 53 years old on average. The prevalence was 48% for regular hypertension and 16% for severe hypertension. The severe hypertension accounted for 33.7% of the regular hypertension. 56.6% of regular hypertension and 59.3% of severe hypertension used antihypertensive medications in the past 2 weeks (Table [1](#T1){ref-type="table"}).

###### 

Characteristics of study population

  Variables                                                      Values
  -------------------------------------------------------------- -------------
  No. of participants                                            1642
  \% of men (No.)                                                39.46%(648)
  Age, years                                                     52.8(10.2)
  BMI, kg/m^2^                                                   24.2(3.7)
  SBP, mmHg                                                      134.9(21.8)
  DBP, mmHg                                                      82.9(10.9)
  Regular hypertension\*                                         48.4%(795)
  Severe hypertension\*\*                                        16.3%(268)
  Antihypertensive medication use,%                              27.41%(450)
  Antihypertensive medication use among regular hypertension,%   56.6%(450)
  Antihypertensive medication use among severe hypertension,%    59.3%(159)
  Gly482Ser genotypes                                            
   S482S                                                         19.24%(316)
   G482S                                                         49.63%(815)
   G482G                                                         31.12%(511)
  +2962A/G genotypes                                             
   +2962A/A                                                      51.16%(840)
   +2962A/G                                                      39.04%(641)
   +2962G/G                                                      9.81%(161)
  Haplotype combination                                          
   S482S\|\|+2962A/A                                             19.0% (312)
   S482S\|\|+2962A/G                                             0.2% (4)
   S482S\|\|+2962G/G                                             0(0)
   G482S\|\|+2962A/A                                             23.9% (392)
   G482S\|\|+2962A/G                                             25.6% (421)
   G482G\|\|+2962A/A                                             8.3% (136)
   G482G\|\|+2962A/G                                             13.2% (216)
   G482S\|\|+2962G/G                                             0.1% (2)
   G482G\|\|+2962G/G                                             9.7% (159)

Data are presented as mean(SD) or %(n);

\* Regular hypertension: SBP ≧ 140 mm Hg or DBP ≧ 90mm Hg or current use of antihypertensive medications;

\*\* Severe hypertension: SBP ≧ 160 mm Hg or DBP ≧ 100mm Hg, regardless of medication use.

Distribution of G482S and +2962A/G genotypes
--------------------------------------------

The frequencies of wild-type (G482G), heterozygous (G482S), and variant genotypes (S482S) were 0.311, 0.496, and 0.192. The frequencies of wild-type (+2962A/A), heterozygous (+2962A/G), and variant genotypes (+2962G/G) were 0.512, 0.390, and 0.098 respectively. The distributions were consistent with Hardy-Weinberg equilibrium (HW-E) for G482S polymorphisms (p = 0.780) but not for +2962A/G (p = 0.018). In addition, the wild-type and variant allele frequencies for G482S polymorphism were 0.559 and 0.441. Respective frequencies for the +2962A/G were 0.707 and 0.293. Estimated haplotype frequencies were 0.269, 0.291, 0.438, and 0.002 for the double-wild-type allele (482G/+2962A), the allele with the variant nucleotide at +2962(482G/+2962G), the allele with the variant nucleotide at G482S (482S/+2962A), double-variant allele (482S/+2962G), respectively. There were no significant differences between men and women in genotype, allele, or estimated haplotype frequencies.

Linkage analyses of G482S and +2962A/G
--------------------------------------

There was significant linkage disequilibrium between the +2962A/G and G482S polymorphism (D\' = 0.981, *p*\< 0.001). The distribution of the +2962A/G polymorphism was significantly associated with the distribution of the G482S polymorphism. The percentage of carriers of +2962 G/G were 0%,0.3%, and 31.1% among carriers of S482S, G482S, and G482G genotypes, and the corresponding percents of carriers of the +2962A/A genotype were 98.7%,48.1%, and 26.6% (p \< 0.0001).

Association of G482S and +2962A/G to blood pressure
---------------------------------------------------

We compared blood pressure among genotype groups. After adjustment for age, sex, body mass index, and current use of antihypertensive medication, SBP and DBP were not significantly associated with G482S genotypes (p = 0.266) or +2962A/G genotypes (p = 0.103) (Table [2](#T2){ref-type="table"}). Sex-specific analyses showed similar results (data not shown in table). In order to exclude the confounding effect of antihypertensive medication, we analyzed the associations in three subgroups: 1) normal blood pressure free from current use of antihypertensive medications; 2) hypertension free from current use of hypertensive medications; 3) current use of antihypertensive medications. We found a significant association of SBP to G482S genotypes (p = 0.023) and +2962A/G genotypes (p = 0.020) in subgroup 3 but not in subgroup 1 or 2 (Table [3](#T3){ref-type="table"}).

###### 

Muti-variable-adjusted means of blood pressure (mm Hg) and standard errors by Gly482Ser and +2962A/G polymorphisms in 1642 participants

  Genotypes            N     SBP(mm Hg)   DBP(mm Hg)
  -------------------- ----- ------------ ------------
  G482S genotypes                         
   G482G               511   139.2(0.9)   85.2(0.5)
   G482S               815   139.4(0.7)   84.7(0.4)
   S482S               316   137.4(1.1)   84.6(0.6)
   p values                  0.266        0.630
  +2962A/G genotypes                      
   +2962A/A            840   138.8(0.7)   84.7(0.4)
   +2962A/G            641   138.6(0.8)   84.9(0.4)
   +2962G/G            161   141.3(1.5)   85.4(0.8)
   p values                  0.103        0.695

Note: values were adjusted for age, sex, BMI, and current use of antihypertensive medications.

###### 

Muti-variable-adjusted means of blood pressure (mm Hg) among Gly482Ser and +2962A/G polymorphism in three subgroups

  Genotypes            Normotensives   Hypertensive free from current antihypertensive medication   Current use of antihypertensive medication                                                     
  -------------------- --------------- ------------------------------------------------------------ -------------------------------------------- ----- ------------ ----------- ----- ------------ -----------
  G482S genotypes                                                                                                                                                                                  
   G482G               250             119.7(0.6)                                                   77.7(0.4)                                    86    150.7(1.4)   90.2(0.9)   155   151.2(1.9)   89.0(1.0)
   G482S               428             120.1(0.5)                                                   77.2(0.3)                                    155   149.6(1.1)   90.8(0.7)   209   152.6(1.6)   88.4(0.8)
   S482S               169             121.3(0.7)                                                   78.2(0.5)                                    61    148.6(1.8)   90.6(1.2)   86    144.8(2.5)   87.0(1.3)
   p values                            0.207                                                        0.286                                              0.647        0.897             0.023        0.426
  +2962A/G genotypes                                                                                                                                                                               
   +2962A/A            429             120.5(0.5)                                                   77.6(0.3)                                    179   149.6(1.1)   90.9(0.7)   232   149.2(1.5)   87.4(0.8)
   +2962A/G            336             120.1(0.5)                                                   77.6(0.4)                                    127   150.2(1.3)   90.0(0.8)   178   151.0(1.8)   89.4(0.9)
   +2962G/G            82              119.4(1.1)                                                   77.2(0.7)                                    39    149.6(2.3)   91.0(1.5)   40    159.9(3.6)   89.4(1.9)
   p values                            0.580                                                        0.899                                              0.930        0.667             0.020        0.181

Means and p values were adjusted for age, sex, and BMI. Values in () are standard errors.

Association of G482S and +2962A/G to hypertension
-------------------------------------------------

The prevalence of regular hypertension varied but did not differ among genotype groups for both G482S and +2962A/G. Adjustment for sex, age, body mass index did not change the results (Table [4](#T4){ref-type="table"}).

###### 

Prevalence and odds ratios (ORs) of regular and severe hypertension by PGC-1*α*polymorphisms in 1642 participants

                             Regular hypertension\*   Severe hypertension\*\*                                                  
  -------------------- ----- ------------------------ ------------------------- --------------- ----- ------- ---------------- -------
  G482S genotypes                                                                                                              
   G482G               511   261                      51.1%                     1.0             91    17.8%   1.0              
   G482S               815   387                      47.5%                     0.9(0.7--1.1)   139   17.1%   1.0(0.8--1.4)    0.503
   S482S               316   147                      46.5%                     0.9(0.7--1.2)   38    12.0%   0.6(0.4--0.98)   0.177
   p values                                           0.335                     0.667                 0.067   0.064            
  +2962A/G genotypes                                                                                                           
   +2962A/A            840   411                      48.9%                     1.0             128   15.2%   1.0              
   +2962A/G            641   305                      47.6%                     0.9(0.7--1.1)   102   15.9%   1.1(0.8--1.4)    0.407
   +2962G/G            161   79                       49.1%                     0.9(0.7--1.4)   38    23.6%   1.9(1.2--3.0)    0.015
   p values                                           0.863                     0.623                 0.030   0.011            

\* Regular hypertension: SBP ≧ 140 mm Hg or DBP ≧ 90mm Hg or current use of antihypertensive medications;

\*\* Severe hypertension: SBP ≧ 160 mm Hg or DBP ≧ 100mm Hg, regardless of medication use.

OR~1~: adjusted for sex, age, BMI.

OR~2~: adjusted for sex, age, BMI, and antihypertensive medication.

P values for prevalence were from Chi-square test, p values for trend of ORs were from logistic regression, and p values for OR~1~vs. OR~2~were from Z-test.

The prevalence of severe hypertension differed at borderline significance among genotype groups for G482S and significantly for +2962A/G. After adjustment for age, sex, body mass index, and current use of antihypertensive medications, risk of severe hypertension was significantly lower for S482S in comparison with that for G482G (OR = 0.6; 95% confidence interval \[CI\]: 0.4--0.98) and significantly higher for +2962G/G than that for +2962A/A (OR = 1.9, 95% CI: 1.2--3.0). Sex-specific OR for +2962G/G vs. +2962A/A were 2.2(95%CI: 1.03--4.5) for men and 1.9(95%CI: 1.1--3.2) for women. However, sex-specific OR for G482S polymorphisms was no longer significant (OR = 0.6, 95%CI: 0.4--1.1 for men, OR = 0.7, 95%CI: 0.4--1.1 for women for S482S vs. G482G).

Association of G482S and +2962A/G haplotype combination to hypertension
-----------------------------------------------------------------------

According to results from Table [4](#T4){ref-type="table"}, we grouped all possible combinations of haplotype into 4 groups as shown in Table [5](#T5){ref-type="table"}. The results clearly showed a synthetic effect of G482S and +2962A/G in developing severe hypertension but not for regular hypertension.

###### 

Haplotype combination analyses of G482S and +2962A/G for regular and severe hypertension in 1642 participants

                             Regular hypertension\*   Severe hypertension\*\*                                                 
  ------------------- ------ ------------------------ ------------------------- --------------- ----- ------- --------------- -------
  S482S\|\|+2962A/X   316    147                      46.5%                     1               38    12.0%   1.0             
  S482S\|\|+2962G/G   0      0                        0                                         0     0                       
  G482X\|\|+2962A/X   1165   569                      48.8%                     1.0(0.8--1.3)   192   16.5%   1.5(1.0--2.2)   0.131
  G482X\|\|+2962G/G   161    79                       49.1%                     1.0(0.7--1.5)   38    23.6%   2.6(1.5--4.4)   0.006
  p values                                            0.753                     0.989                 0.005   0.002           

\* Regular hypertension: SBP ≧ 140 mm Hg or DBP ≧ 90mm Hg or current use of antihypertensive medications;

\*\* Severe hypertension: SBP ≧ 160 mm Hg or DBP ≧ 100mm Hg, regardless of medication use.

OR~1~: adjusted for sex, age, BMI.

OR~2~: adjusted for sex, age, BMI, and antihypertensive medication.

X was used to represents all possible allele, e.g. +2962A/X stands for +2962A/A or +2962A/G.

P values for prevalence were from Chi-square test, p values for trend of ORs were from logistic regression, and p values for OR~1~vs. OR~2~were from Z-test.

Post hoc analysis of power
--------------------------

To understand whether our study has enough statistical power to conclude, we did analysis of power using the number of participants, prevalence of hypertension, and permitted possible type I error. The results showed that we had a power of 90% in analysis for the association of G482S genotype to the risk of severe hypertension, but it was only 46% for regular hypertension. For +2962A/G, we had 99% power for severe hypertension and only 4% for regular hypertension. For haplotype combination, we had 99% power for severe hypertension and only 14% for regular hypertension.

Discussion
==========

Our study has a number of strengths. First, its study population was community-based. Secondly, International standardized methodology and quality control procedures were used, as part of the China Multicenter Collaborative Study of Cardiovascular Epidemiology\[[@B16]\]. Thirdly, genotyping was conducted in the Beijing Genomics Institute Life Tech Co. Ltd. which was one of genotyping centres for the International HapMap Consortium \[[@B17]\]. Theses gave us a better opportunity to detect the true association of our interested genotypes to hypertension.

In our study, G482S and +2962A/G polymorphisms and their haplotypes were found significantly associated with risk of sever hypertension but not with that of regular hypertension. These findings were confirmed by our findings that these two SNPs were significantly associated with blood pressure in patients using antihypertensive medications but not in all participants, normotensives or patients with no medication, and were independent of age, sex, body mass index, and antihypertension medication use. These findings are well in accordance with the current knowledge of hypertension that the disease is caused by not only genetic factors but also environment factors\[[@B3]\]. It is those who exposed to both genetic and environment factors develops severe hypertension and thus had a better power to detect the effect of gene, while those who exposed to only environment factors or genetic factors develops light or moderate hypertension, which should be mostly composed of those caused by environment factors because of the much higher prevalence of environment factors, and it is hardly to detect the effect of gene among them. The dilution effect from environment factors plus the gene\'s \"minor effect\" makes it impossible or very hardly to detect the effect of gene by using a lower cut off to define hypertension. Otherwise, a very large sample of more than tens or hundreds thousands participants is needed to make up, as shown by our post hoc analysis of power. As we knew, this is the first study found that PGC-1*α*gene variants had stronger associations with more severe hypertension. These findings have very important significance of generalization to other studies trying to identifying genes for hypertension development.

In addition, blood pressure lowering treatment in China is generally low (56.6% in this study), and it would be more likely that treated patients have a more severe hypertension and by that have a stronger link to genetic factors.

Our findings are also supported by the previous study done by Oberkofler and colleagues\[[@B6]\]. They used day time ambulatory blood pressure and defined hypertension as SBP \> 140mm Hg or DBP \> 90mm Hg or use of antihypertensive medication, and they found a significant association between G482S and hypertension in men\[[@B6]\]. Because the ambulatory blood pressure is lower than occasional clinic blood pressure, their findings were actually in accordance with ours.

Besides, we also found an additive synthetic effect of G482S and +2962A/G genotypes. Although the mechanisms to explain the effect remain unclear, some studies did provide useful evidence. There is substantial evidence for the existence of both monogenic and polygenic forms of essential hypertension, although these are believed to be modulated by both gene-environment and gene-gene interactions\[[@B8]\]. It is well known that both monogenic and polygenic forms of essential hypertension are often early-onset and more severe \[[@B3]\]. As a coactivator of PPAR*γ*, PGC-1*α*regulates PPAR*γ*gene expression which combined with its ligands (thiazolidinediones) to suppress angiotensin II (AII) type 1 receptor (AT1R) gene expression both at the mRNA and protein levels in vascular smooth muscle cells(VSMCs)\[[@B4]\]. Activation of AT1R by AII binding triggers a variety of signal transduction pathways including the mitogen-activated protein (MAP) kinase pathway. AII exerts many biological effects such as cell construction, proliferation, and migration of VSMCs that contributes to the progression of hypertension and atherosclerosis. PPAR*γ*phosphorylation by the MAP kinase pathway may thus attenuate PPAR*γ*-mediated AT1R gene transcription suppression through the inhibition of PPAR*γ*activity\[[@B18]\]. PGC-1*α*is also a coactivator of other nuclear receptors, including thyroid hormone receptor, the mineralocorticoid and estrogen receptors (ER) *α*and *β*, which are also involved in blood pressure control\[[@B6]-[@B8],[@B19]\].

Our study also has some limitations. First, there were 32% of none-responders in the study. The main reasons of not attending includes busy at farming work, out to do private small business, not having interest, and not like blood being drawn. The possible bias can not be totally eliminated though no reason was associated with hypertension or biological tests. Second, a significant deviation from the Hardy-Weinberg equilibrium (HW-E) was detected for the +2962A/G polymorphism in our study. This contrasts to the previous study by Oberkofler \[[@B6]\]. The findings that G482S genotypes in the same gene were in accordance with HW-E in both studies may not indicate that the deviation from HW-E was directly due to genotyping error. We retyped these polymorphisms independently using sequencing method in eight participants and ensured no genotyping error occurred. Finally, the possibility of type 1 error due to multiple tests is not eliminated but the systematic difference between regular and severe hypertension for both gene SNPs suggested that is not likely the case.

Conclusion
==========

In this study, we found that G482S and +2962A/G SNPs of PGC-1*α*gene were only significantly associated with severe hypertension defined by occasional clinic blood pressure measurements. This finding suggested severe hypertension rather than regular hypertension should be used as the outcome in studies on association of genes and blood pressure or hypertension, in order to have a better power.

Competing interests
===================

The author(s) declare that they have no competing interests.

Authors\' contributions
=======================

GX did literature review, performed the statistical analysis and drafted the manuscript. DG and SL organized the field survey for collection of data. YW and YL designed the study, applied for funding and revised the manuscript. All authors read and approved the final manuscript.

Pre-publication history
=======================

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2261/7/33/prepub>

Acknowledgements
================

This study was supported by grants 30471494 of the National Natural Science Foundation of China, grants 2001BA703B01 of the People\'s Republic of China National 10th Five-Year Plan Science and Technology Key Projects. The authors thank Dr. Min Guo, Ye Tian, and Xianyi Kong for the DNA sampling and preparation for the genotyping. We thank all study participants in their cooperation and valuable contribution. We also thank Chiara Donfrancesco and other members from World Heart Federation CVD Epidemiology Fellows and Faculty list established by Steven Allender for their helps in Z-test of odds ratios.
